For research use only. Not for therapeutic Use.
CTX1（Cat No.:I012913） is a compound known as a p53 activator, capable of counteracting the inhibitory effects of HdmX on p53 function. By activating p53, CTX1 has demonstrated strong anticancer activity in a mouse model of acute myeloid leukemia (AML). AML is a type of blood cancer characterized by the rapid growth of abnormal myeloid cells. The ability of CTX1 to overcome HdmX-mediated p53 repression suggests its potential as a therapeutic agent for treating AML and potentially other cancers where p53 regulation is disrupted.
| Catalog Number | I012913 |
| CAS Number | 501935-96-2 |
| Molecular Formula | C₁₄H₁₀N₄ |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Solubility | DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 3,6-diaminoacridine-9-carbonitrile |
| InChI | InChI=1S/C14H10N4/c15-7-12-10-3-1-8(16)5-13(10)18-14-6-9(17)2-4-11(12)14/h1-6H,16-17H2 |
| InChIKey | PUMGFEMNXBLDKD-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1N)N=C3C=C(C=CC3=C2C#N)N |
| Reference | [1]. Karan G, et al. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Mol Cancer Ther. 2016 Apr;15(4):574-582. |
